Home/Filings/4/0001209191-23-010506
4//SEC Filing

Sherman Matthew L 4

Accession 0001209191-23-010506

CIK 0001654151other

Filed

Feb 16, 7:00 PM ET

Accepted

Feb 17, 4:07 PM ET

Size

9.1 KB

Accession

0001209191-23-010506

Insider Transaction Report

Form 4
Period: 2023-02-15
Sherman Matthew L
EVP & Chief Medical Officer
Transactions
  • Award

    Stock Option (Right to Buy)

    2023-02-15+65,90065,900 total
    Exercise: $15.48Exp: 2033-02-14Common Stock (65,900 underlying)
  • Award

    Common Stock

    2023-02-15+16,48889,116 total
  • Sale

    Common Stock

    2023-02-16$15.10/sh971$14,66188,145 total
Footnotes (3)
  • [F1]The reporting person was awarded 16,488 Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. The RSUs shall vest in three equal installments on each of February 15, 2024, February 15, 2025 and February 15, 2026.
  • [F2]This sale was to cover tax liabilities in the vesting of restricted stock.
  • [F3]This stock option was issued pursuant to the Issuer's 2017 Stock Option and Incentive Plan. The option shall vest in equal monthly installments over four years, beginning on March 15, 2023.

Issuer

Deciphera Pharmaceuticals, Inc.

CIK 0001654151

Entity typeother

Related Parties

1
  • filerCIK 0001325710

Filing Metadata

Form type
4
Filed
Feb 16, 7:00 PM ET
Accepted
Feb 17, 4:07 PM ET
Size
9.1 KB